We are live on
!
Find out more
BCM
Boxer Capital Management Portfolio holdings
AUM
$762M
1-Year Est. Return
1,125.36%
This Fund
S&P 500
This Quarter
Est. Return
+9.43%
1 Year Est. Return
+1,125.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.17B
AUM Growth
–
Cap. Flow
+$1.34B
Cap. Flow
% of AUM
114.29%
Top 10 Holdings %
Top 10 Hldgs %
60.16%
Holding
60
New
60
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$216M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$120M |
| 3 |
NUVL
Nuvalent
NUVL
|
+$105M |
| 4 |
MRUS
Merus
MRUS
|
+$91.2M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$72.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Structure Therapeutics
GPCR
$3.41B
| $13.6M | 1.15% |
+500,000
| New | +$17.7M |
|
|
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
| $13.5M | 1.15% |
+1,590,000
| New | +$16.5M |
|
28
uniQure
QURE
$3.03B
| $13.2M | 1.13% |
+750,000
| New | +$6.47M |
|
29
Cullinan Oncology
CGEM
$1.01B
| $11.1M | 0.94% |
+907,895
| New | +$13.1M |
|
30
Spyre Therapeutics
SYRE
$8.54B
| $10.9M | 0.93% |
+466,680
| New | +$13.7M |
|
31
Nurix Therapeutics
NRIX
$2.41B
| $10.6M | 0.9% |
+563,067
| New | +$12.9M |
|
32
Kodiak Sciences
KOD
$2.6B
| $9.95M | 0.85% |
+1,000,000
| New | +$5.75M |
|
33
Prothena Corp
PRTA
$425M
| $9.56M | 0.81% |
+690,000
| New | +$10.9M |
|
34
Jasper Therapeutics
JSPR
$21M
| $7.48M | 0.64% |
+350,000
| New | +$7.29M |
|
|
ITOS
35
DELISTED
iTeos Therapeutics
ITOS
| $7.27M | 0.62% |
+946,915
| New | +$8.14M |
|
|
CMRX
36
DELISTED
Chimerix, Inc.
CMRX
| $7.17M | 0.61% |
+2,060,000
| New | +$2.91M |
|
37
Instil Bio
TIL
$48.3M
| $6.79M | 0.58% |
+355,500
| New | +$10.8M |
|
38
Amylyx Pharmaceuticals
AMLX
$2.26B
| $6.62M | 0.56% |
+1,750,000
| New | +$8.23M |
|
39
Iovance Biotherapeutics
IOVA
$1.82B
| $5.55M | 0.47% |
+750,000
| New | +$6.95M |
|
|
CLYM
40
Climb Bio
CLYM
$681M
| $4.69M | 0.4% |
+2,603,190
| New | +$9.42M |
|
41
Summit Therapeutics
SMMT
$10.4B
| $4.46M | 0.38% |
+250,000
| New | +$4.85M |
|
|
TERN
42
DELISTED
Terns Pharmaceuticals
TERN
| $4.17M | 0.35% |
+752,000
| New | +$5.09M |
|
43
Keros Therapeutics
KROS
$199M
| $3.96M | 0.34% |
+250,000
| New | +$13M |
|
44
Apogee Therapeutics
APGE
$10.1B
| $3.9M | 0.33% |
+86,000
| New | +$4.39M |
|
45
Olema Pharmaceuticals
OLMA
$1B
| $3.79M | 0.32% |
+650,000
| New | +$6.49M |
|
|
MRSN
46
DELISTED
Mersana Therapeutics
MRSN
| $3.77M | 0.32% |
+105,400
| New | +$5.45M |
|
47
Sana Biotechnology
SANA
$871M
| $2.52M | 0.21% |
+1,545,000
| New | +$4.61M |
|
|
BCAX
48
Bicara Therapeutics
BCAX
$1.78B
| $2.35M | 0.2% |
+135,000
| New | +$2.81M |
|
49
Relay Therapeutics
RLAY
$4.1B
| $2.21M | 0.19% |
+536,132
| New | +$2.92M |
|
50
Prelude Therapeutics
PRLD
$366M
| $2.18M | 0.19% |
+1,708,187
| New | +$2.27M |
|
Similar funds
GWM
FTF
TI
CFS
PMWMG
OM
SIG
CCIP
Boxer Capital Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Boxer Capital Management, which disclosed 60 positions worth $1.17B. Its ten largest holdings account for 60% of the portfolio.
Its largest position is Revolution Medicines: 4,279,464 shares worth $187M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Boxer Capital Management's largest Q4 2024 buy was Revolution Medicines: 4,279,464 shares worth $187M.
- Boxer Capital Management's ten largest holdings make up 60% of its $1.17B portfolio in Q4 2024.
- Boxer Capital Management disclosed 60 positions in Q4 2024, its first 13F filing on record.
Based on Boxer Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.